Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

FGFR1/2/3 inhibitor TYRA-200

An orally bioavailable inhibitor of the tyrosine kinase fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon oral administration, FGFR1/2/3 inhibitor TYRA-200 targets, binds to and inhibits FGFR1/2/3, and is specifically active against certain FGFR2 fusions, molecular brake and gatekeeper resistance mutations. This may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs), is upregulated in many tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:FGFR inhibitor TYRA-200
Code name:TYRA 200
TYRA-200
TYRA200
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search